Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects

Mansoor Raza Mirza,Gabriel Lindahl,Sven Mahner,Andres Redondo,Michel Fabbro,Bobbie J. Rimel,Jorn Herrstedt,Amit M. Oza,Ulrich Canzler,Jonathan S. Berek,Antonio Gonzalez-Martin,Phillipe Follana,Rosemary Lord,Masoud Azodi, Kasey Estenson,Zebin Wang,Yong Li,Divya Gupta,Ursula Matulonis, Bin Feng

Cancer research communications（2022）

引用 0|浏览9

暂无评分

摘要

We retrospectively evaluated the mutational profile of HRR genes in tumor samples from 331 patients from the non-germline -mutated cohort of the phase III NOVA trial of patients with platinum-sensitive high-grade serous ovarian cancer. Patients with non- HRR mutations generally benefited from second-line maintenance treatment with niraparib compared with placebo.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要